Abstract
Cardiovascular diseases, in particular those resulting from atherosclerosis, are currently the leading cause of mortality worldwide. Various risk factors are responsible for the development of atherosclerosis, and with regard to prevention and treatment only those that can be influenced are relevant: smoking, arterial hypertension, type 2 diabetes mellitus, central obesity, metabolic syndrome and hyperlipoproteinemia and dyslipidemia.
High levels of LDL-cholesterol present a particularly high risk, and therefore it is necessary to focus on early detection and treatment of patients with this anomaly. The current pharmacological armamentarium provides sufficient means for that, and these are still expanding, as evidenced by the study ORION with inclisiran.